Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1990 Nov;31(6):365–372. doi: 10.1007/BF01741408

Investigations into the route of uptake and pharmacokinetics of intraperitoneally-administered monoclonal antibodies: I. Transdiaphragmatic blockade of the terminal lymphatics in the rat

Jeffrey S Barrett 1,2, Richard L Wahl 1,✉, John G Wagner 2, Raya Brown 1, Susan J Fisher 1
PMCID: PMC11038613  PMID: 2386982

Abstract

Recent studies on the intraperitoneal administration of radiolabeled monoclonal antibodies indicate that the diaphragm and, in particular, the lymphatics associated with the diaphragm are more involved in the transport of such high-molecular-mass moieties than was earlier suspected. The current study examines the role of the diaphragm in the i.p. transport of an IgG2a murine monoclonal antibody, 5G6.4, by observing the effect on the absorption of the antibody produced when the diaphragm has been scarred. Normal, sham-operated, and diaphragmatically scarred (abrasions made with 600-grade sandpaper) female Sprague Dawley rats (150–250 g) were administered intraperitoneal injections of125labeled 5G6.4 in a volume of 2.0 cm3. Approximately 5 µg antibody protein was administered in the individual 19-µCi injections per rat. Scarring was effective in partially blocking the amount of labeled antibody that crossed the diaphragm. Mean diaphragm levels (% injected dose/g) of125I-labeled 5G6.4 from the scarred group were 16.8% lower than values from the sham-operated rats and 37.2% lower than those from the control rats. The blockade was effective in slowing the appearance of the labeled antibody in the systemic circulation. The half-time to absorption was significantly prolonged in the scarred group; meant1/2 absorption values of 2.5 h for the control group, 5.3 h for the shamoperated group, and 9.6 h for the diaphragmatically blocked group were recorded. Scarring the diaphragm reduced the mean maximum blood concentration by 27.6% over the control group and 23.9% over the sham-operated group. The mean time to maximum blood concentration was lengthened by 93.0% over the control group and 35.3% over the sham-operated group due as a result of scarification. Presumably this impedence to absorption would increase the time that the radiolabeled antibody bathed the peritoneal space. The scarred group also had the largest “system mean residence time” (162.5 h) compared to the sham-operated (147.9 h) and control (118.7 h) groups. These values further verify the effect of surgery on the kinetics of the i.p. administered radiolabeled monoclonals. This work demonstrates that scarifying the diaphragm does alter the kinetics of the i.p. administered monoclonal antibodies and supports the concept that transdiaphragmatic lymphatic absorption is an important route of antibody clearance from the peritoneal cavity.

Keywords: Monoclonal Antibody, Cancer Research, Systemic Circulation, Intraperitoneal Injection, Peritoneal Cavity

Footnotes

H. Helfman Pharmacy Student Aid Fellow

References

  • 1.Albert A, Takamatsu H, Fonkalsrud EW. Absorption of glucose solutions from the peritoneal cavity in rabbits. Arch Surg. 1984;119:1247–1251. doi: 10.1001/archsurg.1984.01390230019004. [DOI] [PubMed] [Google Scholar]
  • 2.Barrett JS, Fisher S, Wagner JG, Wahl RL. Enhanced regional delivery of monoclonal antibodies to the peritoneal cavity by transdiaphragmatic blockade. V Nucl Med. 1989;30:815–815. [Google Scholar]
  • 3.Dedrick RL, Myers CE, Bungay PM, DeVita VT., Jr Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:9–9. [PubMed] [Google Scholar]
  • 4.Dumont AE, Maas WK, Ilieuscu H, Shin RD. Increased survival from peritonitis after blockade of transdiaphragmatic absorption of bacteria. Surg Gynecol Obstet. 1986;162:248–251. [PubMed] [Google Scholar]
  • 5.Flessner MF, Fenstermacher JD, Blasberg RG, Dedrick RL. Peritoneal absorption of macromolecules studied by quantitative autoradiography. Am J Physiol. 1984;248:H26–H32. doi: 10.1152/ajpheart.1985.248.1.H26. [DOI] [PubMed] [Google Scholar]
  • 6.Himmelsbach M, Wahl RL. Studies on the metabolic fate of111In-labeled antibodies. Int J Rad Appl Instrum [B] 1989;16:839–845. doi: 10.1016/0883-2897(89)90169-4. [DOI] [PubMed] [Google Scholar]
  • 7.Laemmli VK. Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature. 1970;222:680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  • 8.Levine S. Postinflammatory increase of absorption from peritoneal cavity into lymph nodes: particulate and oily inocula. Exp Mol Pathol. 1985;43:124–134. doi: 10.1016/0014-4800(85)90062-0. [DOI] [PubMed] [Google Scholar]
  • 9.Leypoldt JK, Parker HR, Frigon RP, Henderson LW. Molecular size dependence of peritoneal transport. J Lab Clin Med. 1987;110:207–216. [PubMed] [Google Scholar]
  • 10.Markwell MAK. A new solid-state reagent to iodinate proteins: I. Conditions for the efficient labeling of antiserum. Anal Biochem. 1982;125:427–432. doi: 10.1016/0003-2697(82)90025-2. [DOI] [PubMed] [Google Scholar]
  • 11.MicroMath Scientific Software 2034 East Fort Union Blvd, Salt Lake City, UT 84121-3144
  • 12.Popovich RP, Moncrief JW, Decherd JF, et al. (1977) Physiological transport parameters in patients in peritoneal and hemodialysis. In: Proceedings of the 10th Annual Contractor's Conference: Artificial Kidney-Chronic Uremia Program. National Institute of Arthritis, Metabolism and Digestive Diseases, pp 95–98
  • 13.SYSTAT Inc. 1800 Sherman Ave. Evanston, Illinois
  • 14.Tsilibary EC, Wissig SL. Lymphatic absorption from the peritoneal cavity: regulation of patency of mesothelial stomata. Microvasc Res. 1983;25:22–39. doi: 10.1016/0026-2862(83)90041-9. [DOI] [PubMed] [Google Scholar]
  • 15.Verger C, Luger A, Moore HL, Nolph KD (1983) Acute changes in peritoneal morphology and transport properties with infectious peritonitis and mechanical injury 23: 823–831 [DOI] [PubMed]
  • 16.Wagner JG. Types of mean residence times. Biopharm Drug Dispos. 1988;9:51–57. doi: 10.1002/bod.2510090106. [DOI] [PubMed] [Google Scholar]
  • 17.Wahl RL, Liebert M. Improved radiolabeled monoclonal antibody uptake by lavage of intraperitoneal carcinomatosis in mice. J Nucl Med. 1989;30:60–65. [PubMed] [Google Scholar]
  • 18.Wahl RL, Liebert M, Carey JE, Jackson G. Quality control of radiolabeled monoclonal antibodies: immunologic and radiochemical. Cancer Drug Deliv. 1985;2:236–236. [Google Scholar]
  • 19.Wahl RL, Liebert M, Biesman B, Roberts J, Jackson G, Kronberg S, Laino L. Production and characterization of a murine monoclonal antibody reactive with ovarian and other epithelial carcinomas. Proc Am Assoc Cancer Res. 1986;27:355–355. [Google Scholar]
  • 20.Wahl RL, Barrett JS, Geatti O, Liebert M, Wilson BS, Fisher S, Wagner JG. The intraperitoneal delivery of radiolabeled monoclonal antibodies: studies on the regional delivery advantage. Cancer Immunol Immunother. 1988;26:187–201. doi: 10.1007/BF00199929. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES